MaxCyte (MXCT) Competitors $1.42 0.00 (0.00%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.46 +0.04 (+2.82%) As of 08/22/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MXCT vs. THRY, RPAY, RMR, SY, TSSI, NUTX, DDI, SOHU, ANPA, and GRVYShould you be buying MaxCyte stock or one of its competitors? The main competitors of MaxCyte include Thryv (THRY), Repay (RPAY), The RMR Group (RMR), So-Young International (SY), TSS (TSSI), Nutex Health (NUTX), DoubleDown Interactive (DDI), Sohu.com (SOHU), Rich Sparkle (ANPA), and GRAVITY (GRVY). These companies are all part of the "business services" industry. MaxCyte vs. Its Competitors Thryv Repay The RMR Group So-Young International TSS Nutex Health DoubleDown Interactive Sohu.com Rich Sparkle GRAVITY MaxCyte (NASDAQ:MXCT) and Thryv (NASDAQ:THRY) are both small-cap business services companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership. Do institutionals & insiders hold more shares of MXCT or THRY? 68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 96.4% of Thryv shares are owned by institutional investors. 3.3% of MaxCyte shares are owned by insiders. Comparatively, 9.9% of Thryv shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, MXCT or THRY? MaxCyte has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Thryv has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Which has higher valuation & earnings, MXCT or THRY? MaxCyte has higher earnings, but lower revenue than Thryv. Thryv is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxCyte$38.63M3.92-$41.06M-$0.43-3.30Thryv$758.29M0.80-$74.22M-$2.37-5.82 Does the media prefer MXCT or THRY? In the previous week, MaxCyte had 1 more articles in the media than Thryv. MarketBeat recorded 1 mentions for MaxCyte and 0 mentions for Thryv. Thryv's average media sentiment score of 1.82 beat MaxCyte's score of 1.58 indicating that Thryv is being referred to more favorably in the news media. Company Overall Sentiment MaxCyte Very Positive Thryv Very Positive Is MXCT or THRY more profitable? Thryv has a net margin of -11.06% compared to MaxCyte's net margin of -125.22%. MaxCyte's return on equity of -22.12% beat Thryv's return on equity.Company Net Margins Return on Equity Return on Assets MaxCyte-125.22% -22.12% -19.10% Thryv -11.06%-47.96%-12.16% Do analysts rate MXCT or THRY? MaxCyte presently has a consensus target price of $7.00, suggesting a potential upside of 392.96%. Thryv has a consensus target price of $21.40, suggesting a potential upside of 55.07%. Given MaxCyte's higher probable upside, research analysts clearly believe MaxCyte is more favorable than Thryv.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MaxCyte 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Thryv 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryMaxCyte and Thryv tied by winning 8 of the 16 factors compared between the two stocks. Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MXCT vs. The Competition Export to ExcelMetricMaxCyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$151.38M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-3.3020.8831.1026.04Price / Sales3.92348.74435.03103.40Price / CashN/A43.1937.7358.48Price / Book0.798.129.536.61Net Income-$41.06M-$54.72M$3.26B$265.56M7 Day Performance4.41%2.63%2.10%1.97%1 Month Performance-39.06%2.78%2.82%-0.36%1 Year Performance-67.36%11.01%30.56%19.03% MaxCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MXCTMaxCyte3.4075 of 5 stars$1.42flat$7.00+393.0%-65.5%$151.38M$38.63M-3.3080Positive NewsTHRYThryv3.017 of 5 stars$12.41-3.6%$21.40+72.4%-23.5%$565.46M$824.16M-5.243,016Positive NewsRPAYRepay3.0351 of 5 stars$5.36+4.1%$7.90+47.4%-32.1%$512.11M$313.04M-35.73580RMRThe RMR Group2.4736 of 5 stars$16.21+1.1%$24.00+48.1%-30.5%$511.31M$897.20M13.85600SYSo-Young International1.8885 of 5 stars$4.60-7.8%$5.50+19.6%-69.3%$506.18M$200.94M-5.751,800Analyst DowngradeTSSITSSN/A$18.83-6.6%N/A+269.3%$504.16M$148M52.3170NUTXNutex Health2.8076 of 5 stars$89.63+1.9%$262.50+192.9%+329.6%$488.41M$479.95M7.541,150Upcoming EarningsDDIDoubleDown Interactive3.9839 of 5 stars$9.50+1.9%$19.25+102.6%-35.4%$461.84M$341.33M3.99220High Trading VolumeSOHUSohu.com3.2721 of 5 stars$15.10-0.7%$20.00+32.5%+0.4%$457.30M$598.40M3.624,300Trending NewsShort Interest ↑ANPARich SparkleN/A$35.34+0.7%N/AN/A$438.62MN/A0.00N/APositive NewsQuiet Period ExpirationGap UpGRVYGRAVITY1.2024 of 5 stars$65.00+4.4%N/A+2.5%$432.57M$350.59M7.79340Analyst DowngradeShort Interest ↓ Related Companies and Tools Related Companies Thryv Alternatives Repay Alternatives The RMR Group Alternatives So-Young International Alternatives TSS Alternatives Nutex Health Alternatives DoubleDown Interactive Alternatives Sohu.com Alternatives Rich Sparkle Alternatives GRAVITY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MXCT) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access